Will Eczema Drug Dupixent Transform Sanofi?
Diabetes treatment was once a major part of drugmaker Sanofi (NASDAQ: SNY), with its blockbuster Lantus bringing in $7 billion in annual sales as recently as six years ago. These days, Lantus' annual sales are more in the area of $3.2 billion, and in December, the company announced it would end its diabetes and cardiovascular research programs. The French drugmaker, with Paul Hudson at the helm since September, has turned a good share of focus to its eczema drug, Dupixent.
Image source: Getty Images.
So far, the numbers are promising. Dupixent's fourth-quarter sales surged 135%, annual sales soared 152% to $2.3 billion, and according to Sanofi, the drug is on its way to the goal of generating peak sales of $11 billion.
Source Fool.com
